[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533486":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":40,"responsibleParty":58,"collaborators":18,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":18,"enrollmentInfo":70,"targetDuration":18,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":18,"overallStatus":43,"whyStopped":18,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"University of Thessaly","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CRRT group","ACTIVE_COMPARATOR","Patients receiving aminoglycosides and submitted to CRRT",[13],"Procedure: Continuous Renal Replacement Therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"no-CRRT group","NO_INTERVENTION","Patients receiving aminoglycosides and no CRRT",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"PROCEDURE","Continuous Renal Replacement Therapy","CRRT",[9],[26],{"name":27,"affiliation":28,"role":29},"Epaminondas Zakynthinos, Prof","University Hospital of Larissa, Intensive Care Unit","PRINCIPAL_INVESTIGATOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":18,"email":35},"Kyriaki Parisi, MD","CONTACT","00306948176845","kyriakiparisi@yahoo.com",{"name":37,"role":33,"phone":38,"phoneExt":18,"email":39},"Vasiliki Tsolaki, PhD","00306972804419","vasotsolaki@yahoo.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Intensive Care Unit, University Hospiatl of Larissa","RECRUITING","Larissa","Thessaly","41110","Greece","GR",{"type":50,"coordinates":51},"Point",[52,53],22.42112,39.62847,{"lat":53,"lon":52},[56,57],{"name":32,"role":33,"phone":34,"phoneExt":18,"email":35},{"name":37,"role":33,"phone":38,"phoneExt":18,"email":39},{"type":29,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Vasiliki Tsolaki","Academic scholar","100533486","aminoglycoside-administration-in-septic-patients-100533486",false,"NCT06226441","Aminoglycoside Administration in Septic Patients","AMASEP","Inclusion Criteria:\n\n* age \\>18 years\n* diagnosis of sepsis or septic shock based on established criteria (Sepsis-3) 29\n* patients with GFR \\\u003C40 ml\u002Fmin\n* microbiemia from a Gram-negative microorganism and for which the attending physician decides to receive an aminoglycoside or sepsis\u002Fseptic shock for which it is decided to administer it\n* signed consent of the patients' next of kin\n\nExclusion Criteria:\n\n* absence of consent\n* known allergic reaction to aminoglycosides\n* infection from strains resistant to aminoglycosides. As long as the patient has received an aminoglycoside (empirical regimen) and the antibiogram follows it, the treatment can be modified based on the judgment of the attending physician, but the patient's data for the time he received the treatment under consideration are recorded and evaluated\n* unattainable placement of a central venous line for renal replacement therapy","ALL","18 Years",{"count":71,"type":72},50,"ESTIMATED","INTERVENTIONAL",[75],"NA","Sepsis is one of the main causes of mortality and morbidity in an ICU setting, while the responsible microorganisms most frequently isolated are multidrug-resistant gram-negative bacteria. Aminoglycoseides (AG) seem to be particularly effective in dealing with these microbes, however their potential toxicity, especially nephrotoxicity, often makes them an unsuitable treatment option. This becomes particularly evident in patients with already impaired renal function, a common occurrence in septic patients requiring ICU treatment. AG are bacteriocidal antibiotics the efficiency of which depends on the maximum concentration in patients' serum (Cpeak).\n\nPathophysiological changes in critically ill patients, result in significant distribution of the drug extravascullary resulting in a decreased concentration of the biologically active component. On the other hand, impaired renal clearance results in high serum drug levels (C trough) making the desired once-daily administration not always achieved.\n\nThe purpose of this study is to test the hypothesis of successful clearance of AG after achieving satisfactory serum levels and therefore their maximum effect minimizing potential toxicity, by using continuous veno-venous haemodiafiltration in patients with sepsis or septic shock and impaired renal function. This way, the aforementioned antibiotics could become a more frequent and potentially earlier choice for physicians in the treatment of sepsis and septic shock patients from multidrug-resistant microbes.",[78,79,80,81],"Sepsis","Septic Shock","Aminoglycoside Toxicity","Renal Replacement Therapy","2024-01-17",{"date":84,"type":85},"2024-01-26","ACTUAL",{"date":87,"type":85},"2023-06-02",{"date":89,"type":72},"2026-12",{"name":5,"class":6},1]